Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Lymphoma, Mantle-Cell 8Recurrence 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, B-Cell 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 217Rituximab 110Etoposide 99Peripheral Blood Stem Cell Transplantation 94Vincristine 91Filgrastim 91Cytarabine 91Methotrexate 90fludarabine phosphate 85Radiotherapy 67Doxorubicin 67Prednisone 66Dexamethasone 57Mycophenolic Acid 53Cyclosporine 53Whole-Body Irradiation 50Busulfan 47Melphalan 44blinatumomab 43Tacrolimus 42fludarabine 41Antilymphocyte Serum 40Methylprednisolone 39merphos 35Calcium Dobesilate 34Leucovorin 33Granulocyte Colony-Stimulating Factor 30Mercaptopurine 26dexamethasone acetate 25dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Burkitt Lymphoma × brexucabtagene autoleucel × Clear all
NCT06144606 2026-03-31

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05537766 2026-03-10

ZUMA-25

Gilead Sciences

Phase 2 Terminated
19 enrolled 28 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡